A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with PD-1 inhibitor orPD-1 inhibitorAlone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy (17000139BLC2002)
(Studie in Planung)

• NORA CA209-653 (Winicker Norimed GmbH):
  A national, prospective, non-interventional study (NIS) of Nivolumab (BMS-936558) in patients with locally advanced or metastatic renal cell carcinoma (stage III/IV) after prior therapy

• T-Rex: Tivozanib - Real World Experience on Tolerability, Patient Reported Outcomes and QoL in 1st line advanced/metastatic RCC

• AVENUE: Avelumab zur Behandlung des Urothelkarzinoms im Praxiseinsatz – die nicht-interventionelle Studie (NIS) AVENUE

• AVION: Real-world evaluation of efficacy and safety with Avelumab (BAVENCIO®) + Axitinib(INLYTA®) in patients with Advanced Renal-Cell CarcinOma(RCC) in multiple EU countries (AVION Study)

• PCO – Studie: Prostata Cancer Outcome Studie (PCO)
  TrueNTH Global Registry im Zertifizierungssystem der DKG.
  Studie zur Verbesserung der Ergebnisqualität beim lokal begrenzten Prostatakarzinom.
• Xofigo - Reassure: seit 2015
  Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC population for long-term Evaluatin. A global non-interventional study

• MukoCell: Anwendungsbeobachtung: BioSeed®-M/ MukoCell®, autologes Mundschleimhauttransplantat zur Anwendung bei rezidivierenden Harnröhrenstrikturen
• Pfizer: STAR-TOR: seit 2008
  Evaluation of safety, Tolerability and Activity: a Registry for Torisel and Sutent-treated patients with advanced or metastatic renal cell carcinoma, mantle cell lymphoma, and gastrointestinal stroma tumor in usual health care setting